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OBJECTIVE—Cytokines are elevated in various insulin-resis-
tant states, including type 2 diabetes and obesity, although the
contribution of interleukin-6 (IL-6) in the induction of these
diseases is controversial.
RESEARCH DESIGN AND METHODS—We analyzed the im-
pact of IL-6 on insulin action in murine primary myocytes,
skeletal muscle cell lines, and mice (wild type and protein-
tyrosine phosphatase 1B [PTP1B] deﬁcient).
RESULTS—IL-6 per se increased glucose uptake by activating
serine/threonine protein kinase 11 (LKB1)/AMP-activated protein
kinase/protein kinase B substrate of 160 kDa (AS160) pathway. A
dual effect on insulin action was observed when myotubes and
mice were exposed to this cytokine: additive with short-term
insulin (increased glucose uptake and systemic insulin sensitiv-
ity) but chronic exposure produced insulin resistance (impaired
GLUT4 translocation to plasma membrane and defects in insulin
signaling at the insulin receptor substrate 1 [IRS-1] level). Three
mechanisms seem to operate in IL-6–induced insulin resistance:
activation of c-Jun NH2-terminal kinase 1/2 (JNK1/2), accumula-
tion of suppressor of cytokine signaling 3 (socs3) mRNA, and an
increase in PTP1B activity. Accordingly, silencing JNK1/2 with
either small interfering RNA or chemical inhibitors impaired
phosphorylation of IRS-1 (Ser307), restored insulin signaling, and
normalized insulin-induced glucose uptake in myotubes. When
using a pharmacological approach, liver X receptor agonists
overcome IL-6–induced insulin resistance by producing down-
regulation of socs3 and ptp1b gene expression. Finally, the lack
of PTP1B confers protection against IL-6–induced insulin resis-
tance in skeletal muscle in vitro and in vivo, in agreement with
the protection against the IL-6 hyperglycemic effect observed on
glucose and insulin tolerance tests in adult male mice.
CONCLUSIONS—These ﬁndings indicate the important role of
IL-6 in the pathogenesis of insulin resistance and further impli-
cate PTP1B as a potential therapeutic target in the treatment of
type 2 diabetes. Diabetes 57:3211–3221, 2008
I
nsulin increases glucose transport in peripheral tis-
sues by mediating translocation of the glucose trans-
porter GLUT4 from an intracellular compartment to
the plasma membrane, an effect that involves acti-
vation of phosphatidylinositol 3-kinase, protein kinase B
(AKT), and some protein kinase C isoforms, as reviewed
(1). Moreover, skeletal muscle has insulin-independent
mechanisms to increase glucose transport, including the
activation of AMP-activated protein kinase (AMPK) by
stimuli, such as hypoxia, ischemia, or exercise, although
the precise role of AMPK in exercise-induced glucose
uptake is still controversial (2). The AKT substrate of 160
kDa (AS160) has emerged as a point of convergence for
both effectors of glucose transport and seems to modulate
GLUT4 trafﬁcking (3). Because skeletal muscle accounts
for the majority of glucose disposal in the body it is,
therefore, the major site for suffering insulin resistance.
Obesity is a risk factor for development of type 2 diabetes,
due in part to the fact that adipose tissue secretes cyto-
kines that may inﬂuence insulin sensitivity. Among these
molecules, tumor necrosis factor (TNF)- and interleukin
(IL)-6 have been proposed as a link between obesity and
insulin resistance because 1) the majority of type 2 dia-
betic patients are obese, 2) TNF- and IL-6 are overex-
pressed in adipose tissues of obese animals and humans,
and 3) elevated plasma concentrations of IL-6 are detected
in obese and insulin-resistant patients (4,5). We previously
investigated how TNF- treatment induces a state of
insulin resistance in vivo and in vitro at the level of insulin
receptor substrate (IRS) (6,7). Accordingly, we identiﬁed
the Ser307 residue in IRS-1 as a site for TNF-–impaired
insulin signaling in myotubes, and p38 mitogen-activated
protein kinase (MAPK) and inhibitor B( I B) kinase are
involved in the phosphorylation of this residue (8).
The role of IL-6 in the etiology of insulin resistance is
not fully understood and has been a matter of controversy
(9). Pretreatment with IL-6 in vivo blunted the ability of
insulin to suppress hepatic glucose production and to
stimulate glucose uptake in skeletal muscle (10). However,
other studies reported a lack of effect or a positive effect of
IL-6 on whole-body glucose disposal in rats and humans,
respectively (11,12). Alternatively, IL-6 induced insulin
resistance in hepatocytes, adipocytes, and myocytes (13–
16). In addition, palmitate-induced IL-6 production led to
inhibition of insulin-stimulated glucose uptake in myo-
cytes, as demonstrated by the prevention of these effects
with anti–IL-6 or anti–Toll-like receptor-2 antibodies
(17,18). The IL-6 protein content in adipose tissue has been
negatively correlated with insulin-stimulated glucose dis-
posal, and a chronic elevation of IL-6 is not desirable
because it may compromise insulin sensitivity (5,19).
Furthermore, a single polymorphism in the IL-6 gene
promoter has been linked to reduced insulin sensitivity
and type 2 diabetes (20).
On the other hand, skeletal muscle also secretes IL-6.
After exercise, IL-6 plasma levels rise because of increased
local production in muscle, and this increase may enhance
substrate metabolism and whole-body glucose homeosta-
sis (21–23). In this regard, an impaired ability to exercise
and to oxidize fatty acids was observed in the IL-6 knock-
out mouse at 3 months of age, and by age 9 months, these
From the
1Department of Biochemistry and Molecular Biology II, Faculty of
Pharmacy, Complutense University, Madrid, Spain; and
2CIBER de Diabetes
y Enfermedades Metabolicas Asociadas.
Corresponding author: Margarita Lorenzo, mlorenzo@farm.ucm.es.
Received 1 August 2007 and accepted 5 September 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 16 Septem-
ber 2008. DOI: 10.2337/db07-1062.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
DIABETES, VOL. 57, DECEMBER 2008 3211mice were obese and insulin-intolerant (24,25). The role of
IL-6 seems to be anti-inﬂammatory in such physiological
situations. Accordingly, in this study, we have evaluated the
impact of IL-6 treatment on insulin sensitivity in skeletal
muscle cells depending on the duration of exposure.
Nuclear receptors comprise a superfamily of related
proteins that act as transcription factors for target genes
involved in glucose and lipid metabolism. These proteins
are activated by naturally produced lipids and by synthetic
compounds, some of which display insulin-sensitizing ef-
fects and anti-inﬂammatory properties (26). Thus, the
effectiveness of different nuclear receptor agonists to
overcome IL-6–induced insulin resistance has also been
evaluated in this work.
Protein-tyrosine phosphatase 1B (PTP1B) acts as a
physiological negative regulator of insulin, which in-
creases expression in muscle and adipose tissue of obese
and diabetic humans and rodents (27,28). In this regard,
transgenic overexpression of PTP1B in muscle decreased
glucose uptake (29); meanwhile, ablation of PTP1B spe-
ciﬁcally in this tissue improved systemic insulin sensitivity
when on a high-fat diet (30). Furthermore, mice lacking
PTP1B also exhibit increased insulin sensitivity under
both dietary or polygenic insulin resistance (31,32). We
recently found upregulation of PTP1B by TNF- and
protection against insulin resistance by this cytokine in
mice and cells lacking PTP1B (6,7). Accordingly, our ﬁnal
goal was to investigate whether PTP1B deﬁciency confers
protection against insulin resistance by IL-6.
RESEARCH DESIGN AND METHODS
Insulin, AICAR, Wortmannin, 4-([E]-2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthalenyl]1-propenyl) benzoic acid (TTNPB), phytanic acid, rosiglitazone,
and antibody anti–-ACTIN were from Sigma-Aldrich (St. Louis, MO);
PD169316, PD98059, and compound C were from Calbiochem-Novabiochem
(La Jolla, CA); SP600125 and GW501516 were from Alexis (Lausen, Switzer-
land); IL-6 was from Roche Diagnostics (Indianapolis, IN); T0901317 was from
Cayman (Ann Arbor, MI); WY14643 was from Biomol (Plymouth, U.K.).
GW3965 was provided by A. Castrillo (Universidad de Gran Canaria, Las
Palmas de Gran Canaria, Spain). Culture media and sera were from Invitrogen
(Paisley, U.K.). Autoradiographic ﬁlms and 11.0 Ci/mmol 2-deoxy-D[1-
3H]glu-
cose were from GE Healthcare (Rainham, U.K.). Antibodies against GLUT1
and GLUT4 were from Chemicon (Temecula, CA); against total and phosphor-
ylated AKT (Ser473), AMPK (Thr172), extracellular signal–regulated kinase
1/2 (ERK1/2) (Thr202/Tyr204), p38MAPK (Thr180/Tyr182), and c-Jun NH2-
terminal kinase 1/2 (JNK1/2) (Thr183/Tyr185) were from Cell Signaling
(Beverly, MA); against IRS-1, IRS-2, P–IRS-1 (Ser307), PTP1B, protein-tyrosine
phosphatase with Src homology 2 domains (SH-PTP2), protein phosphatase
2A (PP2A) and acetyl-CoA carboxylase (ACC) (Ser79) were from Upstate
Biotechnology (Lake Placid, NY); against P-Tyr (sc-508), P-LKB1 (Ser431)
(sc-28465), caveolin-1 (sc-894), IB- (sc-371), and insulin receptor (IR)
(sc-09) were from Santa Cruz (Palo Alto, CA); and against phosphorylated
AS160 (Thr642) were from Biosource (Camarillo, CA). All other reagents used
were of the purest grade available.
Cell culture. Primary myoblasts were obtained from neonatal rat limbs, as
previously described (8). Both rat neonatal myoblasts and mouse C2C12
myoblasts (ATCC, Rockville, MD) were cultured in 10% horse serum–Dulbec-
co’s modiﬁed Eagle’s medium (DMEM) at 37°C and 5% CO2. After reaching
conﬂuence, cells were cultured for 4 days in 2% horse serum–DMEM until
differentiation into multinucleated myotubes. Finally, myotubes were cultured
overnight in serum-free, low-glucose (1,000 mg/l) DMEM supplemented with
1% (wt/vol) BSA before starting different treatments. PTP1B-deﬁcient and
wild-type mouse myocyte cell lines were obtained and cultured as previously
described (7) and shifted for 24 h to serum-free, low-glucose DMEM–BSA
before starting different treatments.
Glucose transport and GLUT4 translocation assays. Glucose uptake was
measured during the last 10 min of culture by incorporation of 2-deoxy-
glucose into cells and expressed as percentage of stimulation over basal
(control  100) as previously described (8). Cells were submitted to subcel-
lular fractionation for plasma membrane and internal membrane isolation
before immunoblotting with GLUT4, GLUT1, and caveolin-1 antibodies (8).
Myoblasts seeded on glass coverslips were differentiated, ﬁxed, and perme-
abilized before incubation with anti-GLUT4 antibody followed by detection
with a ﬂuorescein-conjugated secondary antibody.
Immunoprecipitation and Western blot. Equal amounts of protein from
cell lysates were immunoprecipitated at 4°C with antibodies against IRSs, as
previously described (7). Cellular proteins and immune complexes were
submitted to SDS-PAGE, transferred to Immobilon membranes, and blocked
(7). Immunoreactive bands were visualized using the enhanced chemilumi-
nescence (ECL-Plus) Western blot protocol (Amersham).
Transient transfection with small interfering RNA. Mouse JNK1/2 and
AMPK1/2 small interfering RNAs (siRNAs) and control (RISCfree) siRNA
were purchased from Dharmacon (Lafayette, CO). C2C12 myotubes were
transfected with 50 nmol/l siRNAs using Dharmafect 3 reagent. After 48 h of
transfection, cell lysates were collected and further analyzed.
Real-time quantitative RT-PCR assays. DNase I–treated RNA was reverse
transcribed into cDNA, before performing the PCR assay for ptp1b and
suppressor of cytokine signaling 3 (socs3) gene expression using the Taqman
Gene Expression Assays from Applied Biosystems, as previously described
(6). The results are given as percentage over control (untreated cells) after
normalizing mRNA to 18S rRNA expression.
PTP1B activity. Cells were lysed after culture in phosphate-free–DMEM, as
previously described (7). PTP1B activity was assessed by malachite green and
p-nitrophenylphosphate hydrolysis assays by dephosphorylation of a phos-
phopeptide (RRLIEDAEpYAARG) from Upstate Biotechnology.
Glucose and insulin tolerance tests and preparation of muscle extracts.
Wild-type and whole-body PTP1B-deﬁcient male mice (12 weeks old) were
treated for 3, 24, or 48 h with IL-6 (0.8 g/g body wt i.p.) or vehicle (100 l
PBS–0.1% BSA). Glucose tolerance tests (GTTs) were performed on 24-h-
fasted mice after an intraperitoneal injection of glucose (2 g/kg body wt), and
insulin tolerance tests (ITTs) were performed on fed animals that had
received an intraperitoneal injection of insulin (1 IU/kg body wt), as previ-
ously described (7). Glucose concentration (milligrams per deciliter) was
determined in tail blood samples using an automatic analyzer (Accucheck;
Roche). Mice treated or not with IL-6 were subjected to anesthesia, and
muscle samples from hind legs were removed before and after insulin
stimulation and immediately processed (7). All animal experimentation de-
scribed in this study was conducted in accord with accepted standards of
human animal care.
Data analysis. Results are means  SE from 4–10 independent experiments.
Comparisons between two groups were made by Student’s t test (Figs. 1 and
6). One-way ANOVA was used in Fig. 2A and B and Fig. 5C. Two-way ANOVA
was used in Figs. 2D and F,3 ,4 ,a n d5 A. Differences between groups were
considered statistically signiﬁcant when P values were 0.01.
RESULTS
IL-6 increases glucose uptake by activation of the
LKB1/AMPK/AS160 pathway in myotubes. We investi-
gated the impact of treatment with IL-6 on glucose uptake
and the signaling pathways elicited by this cytokine in
C2C12 myotubes. IL-6 treatment increased glucose uptake
by 40% at 3 h, and this effect was maintained for 24 h (Fig.
1A), with optimal stimulatory effect at 20 ng/ml (Fig. 1B).
IL-6 treatment activated AMPK for 24 h with a peak of
phosphorylation at 3–6 h but failed to activate AKT (Fig.
1C). Moreover, IL-6 also induced phosphorylation of
JNK1/2, p38MAPK, and ERK1/2 for 24 h and activated the
degradation of IB- between 3 and 24 h, with total levels
of these proteins and -ACTIN remaining unchanged.
To investigate the signaling pathways involved in the
induction of glucose uptake by IL-6, we blocked AMPK,
JNK1/2, and AKT by the use of chemical inhibitors and
siRNA (Fig. 1D). The stimulatory effect of IL-6 at3ho n
glucose uptake was completely impaired by compound C,
an inhibitor of AMPK activity that did not preclude its
phosphorylation (33), but was not impaired by wortman-
nin or SP600125, inhibitors of AKT and JNK1/2, respec-
tively. Moreover, when AMPK was knocked down with
siRNA, IL-6 failed to activate glucose uptake, an effect that
was not observed with JNK1/2 or control siRNA. These
data seem to indicate that activation of glucose uptake by
IL-6 is dependent on the activation of AMPK. Accordingly,
IL-6 DUAL ACTION ON INSULIN SENSITIVITY
3212 DIABETES, VOL. 57, DECEMBER 2008we further explored the mechanism by which IL-6 acti-
vates AMPK by examining LKB1, an upstream activator,
and ACC and AS160, downstream targets (2) (Fig. 1E). IL-6
treatment for 3 h produced the sequential phosphorylation
of LKB1, AMPK, ACC, and AS160 in C2C12 cells, and
phosphorylation of ACC and AS160 was prevented by
compound C. When AMPK was knocked down with
siRNA, a robust 80% reduction of AMPK protein was
detected, and, therefore, phosphorylation of AMPK, ACC,
and AS160 by IL-6 was completely impaired.
Short-term IL-6 treatment displays an additive effect
with insulin on glucose uptake, but chronic treat-
ment with this cytokine causes insulin resistance in
myotubes. We explored whether the duration of exposure
to IL-6 was affecting insulin-stimulated glucose uptake in
C2C12 myotubes. Pretreatment with IL-6 for 3 h and stimu-
lation with insulin for 30 min resulted in an additive effect on
glucose uptake that was not observed after treatment with
the cytokine for 6 h (Fig. 2A). However, insulin did not
further stimulate glucose uptake after chronic treatment (24
h) with IL-6, and this inhibitory effect was dose dependent
and maximal at 20 ng/ml (Fig. 2B). In parallel, the phosphor-
ylation of AKT by insulin detected in cells pretreated with
IL-6 for3hw a si m paired at 24 h (Fig. 2C). AKT phosphory-
lation was detected as early as after 5 min of insulin stimu-
lation and remained increased for at least 30 min, the time
required for optimal translocation of GLUT4 to the plasma
membrane (supplementary Figure S1, which is available in
an online appendix at http://dx.doi.org/10.2337/db07-1062).
Insulin decreased the activation of AMPK by IL-6 at 24 h but
not at 3 h. AS160 was phosphorylated by IL-6 and insulin
individually, and when combined, an additive effect was
produced at3ho fIL-6 treatment. In contrast, complete
inhibition of AS160 phosphorylation was observed at 24 h.
These results indicate a reciprocal negative cross talk in the
signaling pathways elicited by insulin and IL-6 under chronic
treatment with the cytokine.
Because mouse C2C12 myotubes did not have an efﬁ-
cient insulin-sensitive phenotype in term of glucose uptake
(34), we explored whether chronic treatment with IL-6
was producing insulin resistance in rat primary neonatal
myotubes, a system previously shown to be sensitive to
insulin (8). Insulin stimulation signiﬁcantly increased
(80%) glucose uptake in neonatal myotubes (Fig. 2D). Cells
pretreated with IL-6 for 24 h showed a 40% higher glucose
uptake than untreated cells, but under this circumstance,
insulin did not further stimulate glucose uptake. The
expression of GLUT4 or GLUT1 was not modiﬁed by
chronic treatment with IL-6 (Fig. 2E). When examining
GLUT4 translocation to the plasma membrane by Western
blot (Fig. 2F) or indirect immunoﬂuorescence (Fig. 2G),
both insulin and IL-6 individually produced this effect, but
when cells were pretreated with IL-6 for 24 h, insulin failed
to translocate GLUT4.
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FIG. 1. IL-6 increases glucose uptake by activation of the LKB1/AMPK/AS160 pathway in C2C12 myotubes. A: C2C12 myotubes were cultured for
up to 24 h in the absence or presence of 20 ng/ml IL-6. Glucose uptake was measured during the last 10 min by incorporation of 2-deoxy-glucose
into the cells. B: Dose-response experiments were performed after IL-6 treatment for 3 h. C: Lysates from cells cultured as in A were analyzed
by Western blot with the corresponding antibodies against total and/or phosphorylated forms of AKT (Ser473), AMPK (Thr172), JNK1/2
(Thr183/Tyr185), ERK1/2 (Thr202/Tyr204), p38MAPK (Thr180/Tyr182), IB-, and -ACTIN. Densitometric analysis of phosphorylated versus
total AMPK (F) and JNK1/2 (Œ) are shown. D: Glucose uptake was determined in cells cultured for 3 h without or with 40 nmol/l wortmannin
(WT), 50 mol/l compound C (CC), or 30 mol/l SP600125 (SP) or for 48 h with 50 nmol/l control siRNA, 50 nmol/l siRNA against JNK1/2, or
AMPK1/2 and then treated for 3 h with 20 ng/ml IL-6. E: Lysates from cells cultured as in D were analyzed by Western blot with the
corresponding antibodies against total and/or phosphorylated forms of LKB1 (Ser431), AMPK, ACC (Ser79), and S160 (hr642). Results in
A–D are expressed as percentage of stimulation over control (100) and are means  SE (n  4–10). Representative experiments of four are shown
in C and E.* P < 0.01, vs. absence of IL-6.
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DIABETES, VOL. 57, DECEMBER 2008 3213Long-term IL-6 treatment inhibits insulin-induced
glucose transport by impairing insulin signaling at
the level of the IRSs in a JNK-dependent manner. To
investigate whether the sustained activation of p38MAPK,
ERK1/2, or JNK1/2 by IL-6 could be contributing to insulin
resistance, these pathways were blocked with chemical
inhibitors as previously described (8). In the presence of
inhibitors, no signiﬁcant changes in insulin- or IL-6–
stimulated glucose uptake were detected either in C2C12
myotubes or neonatal myotubes (Fig. 3A and B). However,
treatment with SP600125 but not with PD98059 or
PD169316 completely restored insulin stimulation of glu-
cose uptake in the presence of IL-6 in both cell types.
These data seem to indicate that although IL-6 activates
several stress kinases, it is mostly JNK1/2 that contributes
to the IL-6 inhibitory effect on insulin action in myocytes.
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3214 DIABETES, VOL. 57, DECEMBER 2008This hypothesis was conﬁrmed by the use of JNK1/2
siRNA, which completely restored insulin-stimulated glu-
cose uptake in the presence of IL-6 (Fig. 3A).
The next step was to identify at which level IL-6 was
interfering with the insulin-signaling cascade and whether
that interference could be avoided when inhibiting JNK1/2.
Insulin-induced tyrosine phosphorylation of IRS-1 and
IRS-2 and serine phosphorylation of AKT was signiﬁcantly
impaired under chronic treatment with IL-6, without sig-
niﬁcant changes in the expression of these proteins (Fig.
3C and D). Moreover, IL-6 produced phosphorylation on
the Ser307 residue of IRS-1 in a JNK-dependent manner
(Fig. 3D). Accordingly, treatment with SP600125 com-
pletely restored phosphorylation of IRS-1 and AKT by
insulin in the presence of IL-6. All of these data indicate
that IL-6–impaired insulin activation of IRS/AKT signaling
cascades in a JNK-dependent manner, in a similar fashion
as detected for glucose uptake. This hypothesis was
conﬁrmed when the JNK1/2 protein was almost com-
pletely knocked down (90%) by the use of siRNA, which
totally blocked phosphorylation of IRS-1 (Ser307) and
reestablished insulin-stimulated AKT phosphorylation in
the presence of IL-6 (Fig. 3E).
Liver X receptor agonists restore insulin action in
the presence of IL-6 by downregulation of socs3 and
ptp1b expression. To overcome insulin resistance pro-
duced by chronic treatment with IL-6, we used ligand
activation of nuclear receptors as a pharmacological ap-
proach (Fig. 4A). From the various compounds tested,
only the liver X receptor (LXR) agonists, GW3965 and, to a
lesser extent, T0901317, completely restored insulin-stim-
ulated glucose uptake in the presence of IL-6, in a similar
fashion to that observed with AKT phosphorylation (Fig.
4B). Furthermore, glucose uptake was not only normalized
by GW3965 treatment but, in fact, improved greatly by
increasing GLUT4 protein content (Fig. 4B), as previously
detected in brown adipocytes (6).
Induction of SOCS3 has been proposed as a mechanism
for IL-6–induced insulin resistance (16). Accordingly, we
determined the accumulation of socs3 mRNA by quantita-
tive RT-PCR in cells cultured in the presence of IL-6, with
or without GW3965 or SP600125, compounds that restored
insulin action in the presence of the cytokine. The expres-
sion of socs3 increased by 40 and 90% after 3 and6ho f
IL-6 treatment, respectively (data not shown), although
maximal accumulation (fourfold) was detected at 24 h
(Fig. 4C). Upregulation of socs3 by IL-6 was completely
impaired by GW3965 and partially impaired by SP600125.
Because activation of PTP1B can contribute to TNF-
insulin resistance (6,7), we determined whether IL-6 treat-
ment was modulating ptp1b expression. We did not detect
changes in ptp1b expression by IL-6 treatment at 3 or 6 h
(data not shown), but at 24 h, a signiﬁcant increase on
ptp1b mRNA accumulation and activity was observed (Fig.
4D and E). However, IL-6 effects on PTP1B expression and
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GW3965 or SP600125.
PTP1B-deﬁcient myocytes do not develop insulin
resistance to glucose uptake by IL-6. Because IL-6
upregulated PTP1B expression, we decided to explore
whether the lack of PTP1B might confer protection
against IL-6–induced insulin resistance (Fig. 5A). Wild-
type myocytes displayed insulin resistance to glucose
uptake by chronic IL-6 treatment in a similar fashion as
C2C12 myotubes or neonatal myotubes (Fig. 2A and D).
However, insulin was able to stimulate glucose uptake
in PTP1B
/ myocytes regardless of the presence of
IL-6. Moreover, in wild-type myocytes, insulin resistance
was detected in terms of tyrosine phosphorylation of IR
and IRS-1 and serine phosphorylation of AKT (Fig. 5B
and C). However, PTP1B-deﬁcient cells displayed acti-
vated insulin signaling regardless of the presence or
absence of IL-6. Furthermore, IL-6 increased the protein
content of PTP1B in wild-type cells, although the con-
tent of other phosphatases, such as SH-PTP2 or PP2A,
remained unaltered.
Modulation of insulin sensitivity by IL-6 in mice: a
lack of PTP1B prevents chronic effects of IL-6. Our
last step was to study whether IL-6 might modulate insulin
sensitivity in vivo in a similar fashion as observed in vitro.
Accordingly, GTTs and ITTs were performed in wild-type
male mice treated for various times with IL-6 (Fig. 6A). An
improvement in GTTs was observed in mice treated for 3 h
with IL-6. However, pronounced and sustained hypergly-
cemia was found in mice treated with IL-6 for 48 h. No
effect was observed at 24 h. Regarding ITTs, an increase in
insulin sensitivity was observed in mice at3ho fIL-6
treatment, without change at 24 h. However, impairment
of the hypoglycemic effect of insulin was produced at 48 h
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normal glucose tolerance and insulin sensitivity after 48 h
with IL-6 (Fig. 6B) indicates that the lack of PTP1B might
protect against systemic insulin resistance by chronic
treatment with this cytokine. Finally, when we studied the
impact of treatment with IL-6 in insulin signaling in
skeletal muscle, again a dual effect was found. At the short
term (3 h), IL-6 activates AMPK without affecting AKT
phosphorylation by insulin. Separately, IL-6 and insulin
activate the phosphorylation of AS160, and together, this
effect was additive (Fig. 6C). In contrast, chronic treat-
ment (48 h) with IL-6 completely impaired insulin-induced
AKT phosphorylation without changes in the amount of
total AKT protein in wild-type mice (Fig. 6D). However,
skeletal muscle from PTP1B-deﬁcient mice showed insu-
lin-stimulated phosphorylation of AKT regardless of the
presence of IL-6. Moreover, an enhancement of PTP1B
protein content in muscle was found in IL-6–treated
wild-type mice. Altogether, these results seem to indicate
that the absence of PTP1B in mice confers protection
against systemic and muscular insulin resistance by the
chronic presence of IL-6.
DISCUSSION
IL-6 has been described as a proinﬂammatory cytokine
that can contribute to insulin resistance in peripheral
tissues when overproduced by adipose tissue (14). How-
ever, IL-6 is also expressed by skeletal muscle during
exercise, with positive metabolic effects that can modulate
insulin action (12,23). So far, the data regarding the impact
of IL-6 in muscle insulin sensitivity are highly controver-
sial. Accordingly, in this study, we explored the hypothesis
that IL-6 effects in skeletal muscle cells may depend on the
duration of exposure. Although IL-6 per se activated
glucose uptake, a dual effect on insulin action was ob-
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FIG. 5. PTP1B-deﬁcient myocytes do not develop insulin resistance to glucose uptake by IL-6. A: Myocytes PTP1B
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insulin (Ins), and glucose uptake was determined. Results were expressed as percentage of stimulation over control (100) and are the mean 
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IP, immunoprecipitation; WB, Western blot.
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DIABETES, VOL. 57, DECEMBER 2008 3217served: short-term IL-6 treatment was additive to insulin
on activating glucose uptake and AS160 phosphorylation,
which resulted in an improvement on glucose tolerance
and insulin sensitivity in mice, whereas chronic exposure
produced insulin resistance both in vitro and in vivo.
IL-6 activates glucose uptake in a dose-dependent man-
ner regardless of the time of treatment as a consequence
of GLUT4 translocation to the plasma membrane in C2C12
myotubes and neonatal myotubes, in a similar fashion as
reported in L6 cells and human skeletal muscle strips,
respectively (12,35). We observed that IL-6 induces the
sequential phosphorylation of LKB1, AMPK, and AS160.
LKB1 was phosphorylated by IL-6 at Ser431, although the
state of phosphorylation of this kinase did not signiﬁcantly
affect LKB1 catalytic activity or its cellular location, as
described previously (36). Furthermore, direct inhibition
of AMPK activity with either compound C or siRNA in the
presence of IL-6 blocked phosphorylation of AS160 and
impeded glucose uptake. Activation of AMPK by IL-6 was
previously observed in skeletal muscle, whereas diminished
AMPK activity was found in muscle from the IL-6 knockout
mice (24). Moreover, deﬁciency of LKB1 in skeletal muscle
was reported to prevent AMPK activation and glucose uptake
during contraction (37), although muscle contraction acti-
vates AMPK by a mechanism independent of direct activa-
tion of LKB1 (38). However, recent observations indicate that
activation of AMPK by cytokines, such as adiponectin,
involves activation of LKB1 in C2C12 cells (39).
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FIG. 6. Modulation of insulin sensitivity by IL-6 in mice: A lack of PTP1B prevents chronic effects of IL-6. Wild-type (A) and PTP1B-deﬁcient (B)
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acute insulin stimulation produced an additive increase in
glucose uptake in C2C12 myotubes. This increase is a
consequence of the activation of AMPK and AKT by IL-6
and insulin, respectively, and is additive to AS160 phos-
phorylation, as observed in C2C12 cells and in skeletal
muscle, in agreement with other reports (3,12,40). More-
over, an improvement in GTTs and ITTs was observed in
mice treated for 3 h with IL-6. This situation can mimic the
positive effect of IL-6 on insulin sensitivity when released
from muscle after exercise (21–24), as schematized in Fig.
7. Chronic exposure (24 h) to IL-6 impaired insulin-
stimulated glucose uptake and GLUT4 translocation in
both C2C12 and neonatal myotubes. Accordingly, insulin-
stimulated IRS-1 and AKT phosphorylation was inhibited
by IL-6. Moreover, no phosphorylation of AMPK or AS160
was detectable, a fact that indicates a reciprocal negative
cross talk in the signaling pathways elicited by insulin and
IL-6 under chronic treatment with the cytokine. Further-
more, IL-6 treatment for 48 h also impaired insulin signal-
ing in skeletal muscle in vivo and caused systemic insulin
resistance as observed from GTTs and ITTs. This situation
imitates the chronic elevation of IL-6 that causes insulin
resistance when secreted by adipose tissue in obesity
(5,19). This dual behavior of IL-6 in insulin-stimulated
glucose uptake has been previously observed in human
skeletal muscle cells (40); meanwhile, inhibition of insulin
signaling by IL-6 was reported in C2C12 cells (15). Recon-
ciliation of our observation of systemic and muscular
insulin resistance in mice treated with IL-6 for 48 h with
the maturity-onset obesity and insulin-intolerance pheno-
type developed by IL-6–deﬁcient mice (25) is not a simple
matter. Accordingly, a very recent study describes reduced
body weight under chronically elevated IL-6 levels (41).
However, these mice also show impaired insulin-stimu-
lated glucose uptake by skeletal muscle, in agreement with
our data. Furthermore, a marked inﬂammation was ob-
served in the liver, an organ whose contribution to the
development of insulin resistance by IL-6 cannot be ruled
out (41).
The molecular mechanism underlying IL-6–mediated
insulin resistance could involve activation of proinﬂamma-
tory kinases, SOCSs, and phosphatases (6,7,16,42). In this
regard, activation of JNK1/2, accumulation of socs3
mRNA, and increases in ptp1b mRNA and activity were
detected in murine myotubes. We found that chronic IL-6
treatment produced phosphorylation of IRS-1 at the resi-
due Ser307, in a JNK-dependent manner, in a similar
fashion to that described in other insulin-resistant states,
such as hyperinsulinemia (43) and TNF- treatment (8).
Accordingly, inhibition of JNK1/2 completely restored
insulin-stimulated glucose uptake and insulin signaling in
the presence of IL-6. Moreover, IL-6 upregulated SOCS3,
which could bind to IR on a key residue for the recognition
of IRS-1, inhibiting its phosphorylation (16,44). Further-
more, we found for the ﬁrst time that IL-6 increased PTP1B
expression and activity, in line with recent observations of
overexpression of PTP1B associated with TNF-–induced
IL-6
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FIG. 7. Dual role of IL-6 in modulating insulin sensitivity in skeletal muscle. IL-6 per se increases GLUT4 translocation to the plasma membrane
by activating the LKB1/AMPK/AS160 pathway. A dual effect on insulin action is observed when myotubes are exposed to this cytokine. Short-term
IL-6 treatment has an additive effect with insulin on glucose uptake, mimicking the positive effect of IL-6 on insulin sensitivity when released from
muscle after exercise. However, chronic exposure (such as when secreted by obese adipose tissue) produces insulin resistance, with impaired
GLUT4 translocation and defects in insulin signaling. Accordingly, IL-6 impairs insulin signaling at the level of IRS-1 by three mechanisms that
involve 1) serine phosphorylation by JNK, 2) impairment on tyrosine phosphorylation by SOCS3, and 3) tyrosine dephosphorylation by PTP1B.
LXR agonists and SP600125 overcome such resistance by producing downregulation of SOCS3 and PTP1B expression and inhibition of JNK,
respectively.
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the accumulation of socs3 and ptp1b mRNA by IL-6 seems
to indicate that activation of JNK1/2 could be involved in
the regulation of these genes, in agreement with the
proposed role of JNK in SOCS3 induction by IL-4 (46).
Accordingly, IL-6 impairs insulin signaling at the level of
IRS-1 by three mechanisms that involve 1) serine phos-
phorylation by JNK, 2) impairment of tyrosine phosphor-
ylation by SOCS3, and 3) tyrosine dephosphorylation by
PTP1B (Fig. 7).
When a pharmacological approach was used to amelio-
rate IL-6–induced insulin resistance, only the synthetic
LXR agonists GW3965 and T0901317 completely restored
insulin-stimulated glucose uptake, an effect that was not
produced by peroxisome proliferator–activated receptor
(PPAR) 
 agonist, although both PPAR
 and LXR are
expressed in skeletal muscle (26,47). This is the ﬁrst time
that the ability of LXR agonists to ameliorate insulin
resistance induced by IL-6 is documented, although
PPAR agonists have been reported to overcome such
resistance in adipocytes (48). The effect produced by
GW3965 on glucose uptake was parallel to a downregula-
tion of socs3 and ptp1b gene expression and to the
recovery of insulin phosphorylation of AKT (Fig. 7). It is
worth mentioning that inhibition of PTP1B activity by
rosiglitazone and T0901317 was reported in skeletal mus-
cle and brown adipocytes under insulin-resistant condi-
tions (6,49). The mechanism of this inhibitory action is
unknown, and thus far no LXR response elements have
been identiﬁed on the ptp1b promoter, although the ex-
pression of other genes such as matrix metalloprotein-
ase-9, induced by cytokines, was repressed by LXR
activation in macrophages (50). Furthermore, recent ob-
servations from our laboratory seem to indicate that LXR
agonists could exert anti-inﬂammatory properties antago-
nizing JNK activation by TNF- in adipose tissue (S.F.-V.,
M.L., unpublished data). Whether this mechanism might
operate in the presence of IL-6 remains to be established.
Finally, this study demonstrates that the deﬁciency in
PTP1B confers protection against IL-6–induced insulin resis-
tance in skeletal muscle either in vitro or in vivo, in agree-
ment with the protection against systemic insulin resistance
observed in mice.
In conclusion, IL-6 produces a dual effect on insulin
sensitivity in myocytes and skeletal muscle: additive at the
short term and negative after chronic exposure. The
mechanism by which long-term IL-6 treatment causes
insulin resistance involves activation of JNK1/2, expres-
sion of socs3, and activation of PTP1B. Accordingly, a
decrease in ptp1b gene expression by treatment with LXR
agonists or by genetic ablation confers protection against
insulin resistance by this cytokine.
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